{
    "2018-06-24": [
        [
            {
                "time": "2023-10-05",
                "original_text": "LLY Scores Win In Alimta Patent Suit, LXRX For The Long Haul, MNKD Breathes Easy",
                "features": {
                    "keywords": [
                        "LLY",
                        "Alimta",
                        "Patent",
                        "LXRX",
                        "MNKD"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Eli Lilly and Company (NYSE:LLY) Is Trading At A 23.26% Discount",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "LLY",
                        "Discount"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Real-World Data Show Advantages in People Treated with Lilly's Once-Weekly TrulicityÂ® (dulaglutide) Compared to Those Treated with Liraglutide and Exenatide QW",
                "features": {
                    "keywords": [
                        "Real-World Data",
                        "Trulicity",
                        "Lilly",
                        "Advantages"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "diabetes"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "5 Biggest Blockbuster Diabetes Drugs of the Future",
                "features": {
                    "keywords": [
                        "Blockbuster",
                        "Diabetes",
                        "Drugs",
                        "Future"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "diabetes"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}